{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"complete response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"partial response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"stable disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"18"}]}],"title":"progressive disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"not evaluable"}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"number of participants responded (complete response, partial response, stable disease, progressive disease, not evaluable) per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0)","groups":[{"description":"Patients receive nintedanib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nNintedanib: Given PO","id":"OG000","title":"Treatment (Nintedanib)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 1 year","title":"Number of Participants Responded (Complete Response, Partial Response, Stable Disease, Progressive Disease, Not Evaluable)","type":"SECONDARY","unitOfMeasure":"Participants"}